Company Filing History:
2 out of 2 
1 out of 41 Years Active: 2022-2025
Title: Innovations of Hyunjung Baek in Cancer Therapy
Introduction
Hyunjung Baek is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of medical science, particularly in the development of innovative therapies for cancer treatment. With a total of 2 patents, his work focuses on utilizing recombinant herpes simplex viruses for targeted cancer therapies.
Latest Patents
One of his latest patents is titled "Recombinant herpes simplex virus having modified glycoprotein gH for retargeting and use thereof." This invention proposes a recombinant herpes simplex virus that has a modified glycoprotein gH, allowing it to specifically target and infect cells with a designated target molecule. This capability makes it particularly useful for anticancer therapy and gene therapy.
Another significant patent is "Recombinant herpes simplex virus having expression cassette expressing fused protein of cancer cell-targeting domain and extracellular domain of HVEM and use thereof." This invention describes a recombinant herpes simplex virus that contains an expression cassette for a fused protein targeting cancer cells. Upon infection, the virus proliferates within the cancer cells, releasing the fused protein, which enhances the infection efficiency of surrounding cancer cells.
Career Highlights
Hyunjung Baek has worked with several prominent organizations, including Gencellmed Inc. and the Korea Institute of Radiological & Medical Sciences. His experience in these institutions has contributed to his expertise in developing innovative medical solutions.
Collaborations
He has collaborated with notable colleagues such as Heechung Kwon and Hyun Yoo Joo, who have also contributed to advancements in the field of cancer therapy.
Conclusion
Hyunjung Baek's innovative work in the realm of recombinant herpes simplex viruses showcases his commitment to advancing cancer treatment methodologies. His patents reflect a promising future for targeted therapies in oncology.